The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

Exact Sciences Corp EXAS Stock XNAS Rating as of Aug 1, 2025 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends Ownership Executive ...

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

Exact Sciences is beginning to stem losses and is continuing to grow revenue at a reasonable clip. Despite this, GAAP profitability is still far into the future, and the 2023 guidance is mediocre.

Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.

First, more providers than ever are now prescribing Cologuard. Exact Sciences recently reported that around 147,000 providers have adopted the DNA cancer test, which reflects a CAGR of 76% since 2014.

Exact Sciences Corporation EXAS is well poised for growth in the coming quarters, led by strong Cologuard growth. The raised 2023 guidance is a major upside. However, mounting expenses and stiff ...

Review the current valuation for Exact Sciences Corp (EXAS:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.